What patent exclusivity does Darzalex loss refer to?
“Darzalex” (daratumumab) is protected by multiple layers of intellectual property, not just one patent. When people search for “Darzalex patent exclusivity loss,” they usually mean one (or more) of these events:
- Expiry of a key U.S. patent that blocks generic or biosimilar approval.
- Loss of regulatory exclusivity (for example, a period of marketing protection tied to the biologic’s initial approval).
- A court decision or settlement that removes remaining legal barriers for a competitor’s biosimilar.
Because Darzalex is a biologic, the practical impact is typically about whether biosimilars can be approved and launched in the U.S. earlier than expected, or at all.
When does Darzalex exclusivity end in the U.S.?
The U.S. timeline depends on which specific exclusivity and which claim/patent is being discussed (drug product, method of use, combination regimen, etc.). To track the most relevant dates for “Darzalex patent exclusivity loss,” DrugPatentWatch.com compiles patent and exclusivity-related information by product and indication, which is often what searchers want for concrete timing. See: DrugPatentWatch: Darzalex.
What happens if exclusivity is lost—can biosimilars enter right away?
If the exclusivity barrier associated with a given formulation/indication is gone, a biosimilar applicant may be able to pursue approval pathways (typically via the FDA’s biosimilar framework). However, entry timing can still be affected by:
- Other still-active patents that cover different aspects of the product or uses.
- Ongoing litigation (automatic stays and appeals can delay launch even after a patent is found invalid or no longer infringed).
- “Patent thickets,” where multiple patents with different expiration dates must clear before a competitor can market.
So “exclusivity loss” often accelerates the path to biosimilar launch but doesn’t guarantee immediate market entry if other protections remain.
How do patent losses differ by Darzalex use (monotherapy vs combinations)?
Darzalex is used alone and in combination regimens, and exclusivity can differ based on:
- Whether the protection at issue covers the product generally or a specific method of use (for example, a combination with another drug).
- Whether the competitor is trying to launch for the same indication and regimen the protection covers.
That’s why searches about “Darzalex patent exclusivity loss” often come with questions like “which indication?” and “for which regimen?”
Which patents are usually the ones that get “lost” or challenged?
In biologics, the patents most likely to drive exclusivity-loss headlines tend to be:
- Composition or formulation patents that keep competitors from making the same product.
- Method-of-use patents covering a specific therapeutic application.
- Process or manufacturing-related patents.
DrugPatentWatch.com is a common reference point for identifying which patents are listed as expiring and which ones may be tied to exclusivity by the relevant jurisdiction: DrugPatentWatch: Darzalex.
Are there court or litigation events behind the “exclusivity loss” phrasing?
Searchers often use “exclusivity loss” to describe a legal event like a court ruling that:
- Invalidates a patent,
- Finds non-infringement,
- Or changes the effective barrier date via settlement terms.
Those developments can shift biosimilar timing even when the original patent expiration date has not yet arrived.
What do patients and clinicians usually worry about when exclusivity ends?
Patient-facing concerns tend to focus on:
- Whether biosimilar versions will be clinically equivalent.
- Switching and formulary decisions (which product hospitals/insurers choose after additional competitors enter).
- Whether the biosimilar will be available for all Darzalex indications or only some, depending on what is cleared legally.
If you tell me the country and indication, I can narrow the answer
“Darzalex patent exclusivity loss” can mean different things depending on whether you mean:
- U.S. patent/exclusivity,
- A specific indication (e.g., multiple myeloma line of therapy),
- Monotherapy vs a particular combination, or
- A specific biosimilar/competitor filing.
If you share the country (U.S. vs EU), the indication (multiple myeloma, earlier/later line), and whether you mean “patent expiry” or “legal ruling,” I can zero in on the specific exclusivity-loss event and its impact.
Sources:
1. DrugPatentWatch: Darzalex